Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-21 02:50 | 2025-03-18 | RNAC | Cartesian Therapeutics, Inc. | SPRINGER TIMOTHY A | Director, 10% owner | BUY | $15.26 | 89,863 | $1,371,157 | 8,621,325 |
| 2025-03-21 02:38 | 2025-03-19 | BMRN | BIOMARIN PHARMACEUTICAL INC | Burkhart Erin | Officer | SELL | $71.52 | 1,295 | $92,618 | 16,955 |
| 2025-03-21 01:15 | 2025-03-18 | DVAX | Dynavax Technologies Corporation | Novack David F | Officer | SELL | $13.58 | 14,020 | $190,392 | 8,078 |
| 2025-03-20 23:14 | 2025-03-19 | ANIP | Ani Pharmaceuticals Inc. | Davis Krista | Officer | SELL | $65.00 | 1,866 | $121,290 | 64,659 |
| 2025-03-19 23:47 | 2025-03-17 | NUVL | Nuvalent, Inc. | Porter James Richard | Director, Officer | OPT+S | $75.87 | 27,000 | $2,048,563 | 249,062 |
| 2025-03-19 23:47 | 2025-03-17 | CNTA | Centessa Pharmaceuticals plc | CHAO DAVID M | Officer | OPT+S | $17.17 | 7,000 | $120,206 | 225,007 |
| 2025-03-19 23:47 | 2025-03-17 | CNTA | Centessa Pharmaceuticals plc | HUSSAIN IQBAL J | Officer | OPT+S | $16.45 | 6,000 | $98,697 | 105,386 |
| 2025-03-20 00:40 | 2025-03-18 | MIRM | Mirum Pharmaceuticals, Inc. | Howe Jolanda | Officer | SELL | $44.45 | 2,415 | $107,343 | 2,426 |
| 2025-03-20 00:53 | 2025-03-17 | KNSA | Kiniksa Pharmaceuticals International, plc | Ragosa Mark | Officer | OPT+S | $23.10 | 20,343 | $469,923 | 23,382 |
| 2025-03-20 00:29 | 2025-03-17 | NAMS | NewAmsterdam Pharma Co N.V. | Kling Douglas F | Officer | OPT+S | $0.00 | 100,000 | $0 | 44,000 |
| 2025-03-19 23:32 | 2025-03-17 | TRDA | Entrada Therapeutics, Inc. | WENTWORTH KORY JAMES | Officer | SELL | $10.67 | 1,784 | $19,035 | 109,536 |
| 2025-03-19 18:47 | 2025-03-17 | ZOM | Zomedica Corp. | Jordan Scott | Officer | BUY | $0.06 | 300,000 | $18,600 | 300,000 |
| 2025-03-20 00:42 | 2025-03-17 | ELVN | Enliven Therapeutics, Inc. | Kintz Samuel | Director, Officer | SELL | $20.83 | 12,500 | $260,320 | 990,392 |
| 2025-03-19 23:41 | 2025-03-17 | ZLAB | Zai Lab Ltd | Amado Rafael | Officer | SELL | $38.41 | 3,000 | $115,230 | 30,834 |
| 2025-03-19 23:48 | 2025-03-17 | VSTM | Verastem, Inc. | Paterson Dan | Director, Officer | SELL | $6.95 | 244 | $1,696 | 346,479 |
| 2025-03-19 23:46 | 2025-03-17 | VSTM | Verastem, Inc. | Stuglik Brian M | Director | SELL | $6.95 | 593 | $4,121 | 94,587 |
| 2025-03-19 23:47 | 2025-03-17 | VSTM | Verastem, Inc. | Gagnon Robert E. | Director | SELL | $6.95 | 284 | $1,974 | 34,193 |
| 2025-03-20 01:32 | 2025-03-17 | ZYME | Zymeworks Inc. | EcoR1 Capital, LLC | Director, 10% owner | BUY | $12.55 | 228,463 | $2,866,548 | 17,030,604 |
| 2025-03-19 23:03 | 2025-03-18 | ESPR | Esperion Therapeutics, Inc. | Halladay Benjamin | Officer | SELL | $1.48 | 3,535 | $5,242 | 481,710 |
| 2025-03-19 23:02 | 2025-03-18 | ESPR | Esperion Therapeutics, Inc. | Warren Eric | Officer | SELL | $1.49 | 2,433 | $3,618 | 370,326 |
| 2025-03-19 23:02 | 2025-03-18 | ESPR | Esperion Therapeutics, Inc. | Koenig Sheldon L. | Director, Officer | SELL | $1.50 | 13,047 | $19,623 | 1,571,962 |
| 2025-03-19 23:01 | 2025-03-17 | PTGX | Protagonist Therapeutics, Inc | Waddill William D. | Director | SELL | $54.25 | 4,000 | $217,000 | 13,130 |
| 2025-03-19 15:06 | 2025-03-18 | ARVN | Arvinas Inc. | Berkowitz Noah | Officer | SELL | $8.59 | 8,658 | $74,372 | 110,023 |
| 2025-03-19 23:30 | 2025-03-18 | ALZN | Alzamend Neuro Inc. | Horne William B. | Director | BUY | $0.97 | 5,000 | $4,852 | 21,666 |
| 2025-03-20 01:47 | 2025-03-18 | CLNN | Clene Inc. | General Resonance LLC | 10% owner | SELL | $4.42 | 2,733 | $12,092 | 710,852 |
| 2025-03-19 22:31 | 2025-03-18 | NIKA | NIKA PHARMACEUTICALS, INC | Savov Dimitar Slavchev | Director, Officer, 10% owner | SELL | $0.25 | 2,000,000 | $500,000 | 455,589,500 |
| 2025-03-19 23:01 | 2025-03-17 | GYRE | GYRE THERAPEUTICS, INC. | Ma Songjiang | Director, Officer | SELL | $11.89 | 2,242 | $26,658 | 2,829,018 |
| 2025-03-19 23:53 | 2025-03-17 | INSM | INSMED Inc | Lewis William | Director, Officer | OPT+S | $77.03 | 25,580 | $1,970,420 | 233,924 |
| 2025-03-19 01:35 | 2025-03-14 | BCAX | Bicara Therapeutics Inc. | Meisner Lara | Officer | OPT+S | $12.90 | 79,146 | $1,021,213 | 0 |
| 2025-03-19 02:01 | 2025-03-17 | LYEL | Lyell Immunopharma, Inc. | Newton Charles W. | Officer | BUY | $0.56 | 200,000 | $111,620 | 200,000 |
| 2025-03-19 04:54 | 2025-03-14 | VREO | Vireo Growth Inc. | Chicago Atlantic Credit Opportunities, LLC | 10% owner | BUY | $0.38 | 123,022 | $46,798 | 313,522 |
| 2025-03-19 04:30 | 2025-03-17 | MIRM | Mirum Pharmaceuticals, Inc. | Howe Jolanda | Officer | OPT+S | $44.35 | 57,606 | $2,554,763 | 4,841 |
| 2025-03-19 00:30 | 2025-03-17 | AKRO | Akero Therapeutics, Inc. | Yale Catriona | Officer | OPT+S | $44.76 | 10,000 | $447,605 | 95,034 |
| 2025-03-18 23:48 | 2025-03-17 | ZOM | Zomedica Corp. | MACLEOD CHRISTOPHER ROSS | Director | BUY | $0.06 | 143,000 | $8,437 | 143,000 |
| 2025-03-18 23:36 | 2025-03-17 | ZOM | Zomedica Corp. | Klass Russell Kevin | Officer | BUY | $0.07 | 699,980 | $48,999 | 3,200,030 |
| 2025-03-18 23:24 | 2025-03-17 | ZOM | Zomedica Corp. | Williams Rodney James | Director | BUY | $0.07 | 100,000 | $6,900 | 100,000 |
| 2025-03-18 23:27 | 2025-03-14 | PRLD | Prelude Therapeutics Inc | Vaddi Krishna | Director, Officer | BUY | $0.75 | 39,105 | $29,462 | 1,303,880 |
| 2025-03-19 01:45 | 2025-03-17 | VRCA | Verrica Pharmaceuticals Inc. | Hayes Christopher G. | Officer | SELL | $0.65 | 4,315 | $2,805 | 176,458 |
| 2025-03-18 23:51 | 2025-03-14 | BGNE | BeOne Medicines Ltd. | Wu Xiaobin | Officer | SELL | $0.00 | 0 | $0 | 0 |
| 2025-03-19 04:30 | 2025-03-17 | MIRM | Mirum Pharmaceuticals, Inc. | Radovich Peter | Officer | OPT+S | $44.21 | 7,879 | $348,364 | 18,672 |
| 2025-03-19 04:16 | 2025-03-14 | RYTM | RHYTHM PHARMACEUTICALS, INC. | Mazabraud Yann | Officer | OPT+S | $51.48 | 75,000 | $3,861,270 | 40,370 |
| 2025-03-18 23:52 | 2025-03-17 | ZOM | Zomedica Corp. | Rowe Jeffrey M | Director | BUY | $0.07 | 1,439,005 | $96,126 | 1,714,005 |
| 2025-03-19 04:30 | 2025-03-17 | MIRM | Mirum Pharmaceuticals, Inc. | Peetz Christopher | Director, Officer | OPT+S | $44.21 | 27,279 | $1,206,122 | 138,641 |
| 2025-03-19 03:07 | 2025-03-14 | LYEL | Lyell Immunopharma, Inc. | Klausner Richard | Director | BUY | $0.60 | 158,000 | $94,942 | 843,365 |
| 2025-03-19 00:00 | 2025-03-14 | ABBV | AbbVie Inc. | Reents Scott T | Officer | SELL | $212.34 | 17,644 | $3,746,527 | 11,577 |
| 2025-03-18 19:27 | 2025-03-17 | APLS | Apellis Pharmaceuticals Inc. | Chopas James George | Officer | SELL | $24.82 | 183 | $4,543 | 47,955 |
| 2025-03-19 00:04 | 2025-03-14 | MIRM | Mirum Pharmaceuticals, Inc. | Heron Patrick J | Director | BUY | $44.11 | 549 | $24,214 | 168,672 |
| 2025-03-19 01:59 | 2025-03-14 | LYEL | Lyell Immunopharma, Inc. | Seely Lynn | Director, Officer | BUY | $0.61 | 175,000 | $106,190 | 712,500 |
| 2025-03-18 23:15 | 2025-03-17 | ALT | Altimmune, Inc. | Sohn Catherine A. | Director | BUY | $5.78 | 1,000 | $5,785 | 1,000 |
| 2025-03-18 23:38 | 2025-03-17 | ZOM | Zomedica Corp. | Blair Anthony K | Officer | BUY | $0.06 | 500,000 | $30,000 | 900,000 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.